| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8218001 | International Journal of Radiation Oncology*Biology*Physics | 2014 | 7 Pages |
Abstract
[18F]fluorodeoxyglucose positron emission tomography is an early indicator of outcomes in patients with RMS. Future prospective trials may incorporate FDG-PET response data for risk-adapted therapy and early assessment of new treatment regimens.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
![Predicting Outcome in Patients with Rhabdomyosarcoma: Role of [18F]Fluorodeoxyglucose Positron Emission Tomography](/preview/png/8218001.png "First Page Preview: Predicting Outcome in Patients with Rhabdomyosarcoma: Role of [18F]Fluorodeoxyglucose Positron Emission Tomography")
Authors
Dana L. BA, Leonard H. MD, Josef J. MD, Kavita V. MD, Heiko MD, Alison N. MD, Suzanne L. MD,